Price Forecast:

Bullish Case: MYGN’s ongoing strategic partnerships and innovative cancer genomic testing could lead to increased revenues, especially if healthcare coverage stabilizes post-election, boosting investor confidence.

Bearish Case: The recent withdrawal of UnitedHealthcare's coverage could significantly undermine MYGN’s revenues, coupled with high market volatility and enduring investor skepticism, pressuring stock performance.

Potential Outcomes:

1. 40% chance: MYGN stabilizes around current levels due to supportive market trends and new partnerships.

2. 30% chance: Continued stock decline driven by unfavorable market reactions post-healthcare policy changes.

3. 20% chance: Moderate growth triggered by new product successes and improved market sentiments.

4. 10% chance: Major upside from recovering healthcare reimbursements and strategic market positioning.

Trading Oracle: Consider executing a long call debit spread between strikes $18-$20, targeting expiration in 60 days. This leverages the expected increase in volatility from anticipated product launches while minimizing loss exposure from bearish sentiment. The high implied volatility reflects potential price movement; capitalize while limiting risk via spreads.

November 15, 2024